Business Context and Reporting Period
Company: Dr. Reddy's Laboratories Limited
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Filing Date: May 07, 2024
Reporting Period: Quarter and fiscal year ended March 31, 2024
This filing serves as a disclosure of results of operations and financial condition. The registrant has furnished the SEC with press releases and audited financial results prepared under International Financial Reporting Standards (IFRS) and Indian Accounting Standards (Ind AS).
Key Financial Metrics
Revenue, Profit, Cash Flow, Margins, Debt, and Liquidity: The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the attached exhibits (Exhibits 99.2, 99.3, 99.4, and 99.5) which are referenced but not included in the text of this Form 6-K.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. It only confirms the announcement of results for the quarter and year ended March 31, 2024.
Guidance, Outlook, and Risks
Management Commentary and Outlook: The text does not include specific management commentary, forward-looking guidance, or risk factors. It directs readers to the attached press release and financial statements for detailed information.
Unusual Items: No unusual items are described in the text of this filing.
Investor Verification Checklist
- Review Exhibit 99.2 (Press Release) for the official announcement of Q4 FY2024 financial results.
- Examine Exhibit 99.3 for IFRS Audited Consolidated Financial Results to verify revenue and profit figures.
- Check Exhibit 99.4 for Ind AS Audited Consolidated Financial Results for local regulatory compliance data.
- Refer to Exhibit 99.5 for Ind AS Audited Standalone Financial Results.
- Verify the Outcome of the Board Meeting held on May 07, 2024, as detailed in Exhibit 99.1.